Oncternal Therapeutics, Inc. (ONCT)


+0.09 (+24.78%)
Symbol ONCT
Price $0.431
Beta 1.305
Volume Avg. 0.15M
Market Cap 25.416M
Shares () -
52 Week Range 0.26-1.33
1y Target Est -
DCF Unlevered ONCT DCF ->
DCF Levered ONCT LDCF ->
ROE 34.82% Strong Buy
ROA -95.36% Strong Sell
Operating Margin -
Debt / Equity -0.18% Neutral
P/E -0.60
P/B -0.13 Neutral


Consensus EPS

Upgrades & Downgrades

Latest ONCT news

Dr. James B. Breitmeyer M.D., Ph.D.
NASDAQ Capital Market

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.